Investigation of the association between interleukin-1β polymorphism and normal tension glaucoma by Wang, Chun Yuan et al.
 Molecular Vision 2007; 13:719-23 <http://www.molvis.org/molvis/v13/a77/>
Received 17 January 2007 | Accepted 14 May 2007 | Published 14 May 2007
 Glaucoma is a degenerative optic neuropathy character-
ized by loss of retinal ganglion cells, cupping of the optic nerve
head, and visual field defects often related to elevated intraocu-
lar pressure. The disease affects approximately 70 million
people worldwide and is the second most common cause of
blindness [1]. Factors other than IOP are likely to have a role
in the pathogenesis of glaucomatous optic neuropathy, par-
ticularly in individuals with normal tension glaucoma (NTG).
NTG is a subtype of primary open angle glaucoma (POAG)
and accounts for one-third of all cases of POAG [2]. Patients
with NTG show IOP measurements within the statistically
normal range, and these patients usually present late in life
after a visual field defect has occurred. A genetic approach is
needed to identify those at risk of developing NTG.
Recent laboratory evidence shows a connection between
abnormal autoimmunity and NTG, suggesting NTG may be a
glaucomatous condition affected by antibodies damaging reti-
nal tissue and inducing apoptosis. Wax et al. [3] found deposi-
tion of IgG, IgA, and retinal antibodies in the retinal ganglion
cell of NTG patients. Fellman et al. [4] noted that patients
with NTG and rheumatoid disease have a high level of serum
antibodies to rhodopsin and heat shock protein 60.
Shinji et al. [5] found interleukin-1β (IL-1β) plays an im-
portant role in mediating ischemic and excitotoxic damage in
the retina in glaucoma. Proinflammatory cytokines, such as
IL-1, as well as other indicators of microglial activation, have
been suggested as drivers of neuropathological changes in
several neurodegenerative conditions.
Vickers et al. [6] presented evidence that the neuronal
pathology of Alzheimer’s disease contributes to an aberrant
regenerative response of nerve cells triggered by the gradual
compression and physical damage to axons within beta-amy-
loid plaques that form in the brain. Glaucoma may be a chronic
neurodegeneration like Alzheimer’s disease, because similar
evidence also indicates there is beta-amyloid build-up in reti-
nal ganglion cells in rats with experimental glaucoma [7,8].
In this regard, glaucoma may be viewed as a chronic
neurodegenerative disease similar to Alzheimer’s disease, and
a slow build up of beta-amyloid in the ganglion cell may even-
tually trigger cell death and optic nerve axon loss. There is
evidence that the IL-1 protein may act to promote the devel-
opment of beta-amyloid deposits [9-12].
Researchers have noted several polymorphic regions in
the IL-1β gene. A C/T polymorphism at position -511 of the
IL-1β gene in the promoter region has been reported to be
associated with Alzheimer’s disease, with the IL-1β(-511) T
allele polymorphism found to increase the risk for late-onset
Alzheimer’s disease [13-15]. The other polymorphism in IL-
1β (at position +3953 in exon 5) has shown an association
with the risk for Alzheimer’s disease [16].
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Purpose: In normal tension glaucoma (NTG), factors other than elevated intraocular pressure are likely to have a role in
the pathogenesis of optic neuropathy. The potential similarities in cellular apoptosis leading to neurodegeneration be-
tween Alzheimer’s disease and NTG were shown in recent studies. The interleukin-1β (IL-1β; -511) and IL-1β (+3953)
polymorphisms were found to increase risk with Alzheimer’s disease. The purpose of this study was to test the hypothesis
that the IL-1β polymorphism is associated with NTG in the Chinese population.
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Genomic DNA was amplified by a polymerase chain reaction, followed by the enzymatic restriction fragment length
polymorphism technique. Patients and controls were genotyped for the C/T polymorphism at position -511 and +3953 of
the IL-1β gene. Genotypes for NTG and control groups were compared for statistically significant differences.
Results: There was no significant difference in genotype frequency or allele frequency distribution of the IL-1β gene
polymorphisms (position -511 and +3953) between NTG patients and the control group (p >0.3).
Conclusions: Our study showed no evidence for an association between the IL-1β (-511) and IL-1β (+3953) polymor-
phisms and NTG. The IL-1β gene polymorphisms (position -511 and +3953) may not play a key role in NTG pathogenesis
in Chinese population.
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719NTG may be a chronic neurodegeneration like
Alzheimer’s disease. Given the potential similarities in cellu-
lar events leading to neurodegeneration between Alzheimer’s
disease and glaucoma, we hypothesized that the IL-1β (-511)
and IL-1β (+3953) polymorphisms, because of the effect on
IL-1 protein expression, may predispose affected individuals
to glaucoma. We therefore sought to investigate the distribu-
tion of IL-1β (-511) and IL-1β (+3953) polymorphisms in NTG
patients and compare them with a healthy control population.
METHODS
Subjects:  Subjects were recruited at the outpatient clinic in
the Department of Ophthalmology at the Veterans General
Hospital, Taichung, Taiwan from January 2004 to February
2007. NTG patients were approached as they visited the clinic
for previously scheduled visits and were enrolled after con-
senting to participate in the study. Normal control subjects
were recruited during their visits to the outpatient clinic for
various other reasons. Written informed consent was obtained
from all study subjects prior to enrollment. The study was car-
ried out with the approval of the Human Study Committee of
the Veterans General Hospital.
All participants received comprehensive ophthalmologic
examinations including visual acuity testing with refraction,
IOP measurement, Humphrey 30-2, slit lamp examination, and
dilated slit lamp stereobiomicroscopy. Comprehensive oph-
thalmologic history and longitudinal follow data were also
obtained for each individual. The definition for NTG included
the presence of typical glaucomatous optic neuropathy with
compatible visual field defects (arcuate, Bjerrum, Seidel and/
or paracentral scotoma and/or nasal step on Humphrey 30-2),
open anterior chamber angle, and absence of any contributing
ocular or systemic disorders. Patients with NTG had untreated
IOP measurements that were consistently 21 mmHg or lower
on diurnal test and at follow-up.
Unrelated control subjects were recruited from clinic pa-
tients who were seeking treatment for senile cataract, floater,
refractive errors, or itchy eye. All normal control subjects had
no systemic disease and no family history of glaucoma. They
were excluded from glaucoma using the same criteria of diag-
nosis as the NTG patients after the same ophthalmic examina-
tion procedure.
DNA preparation and genotype identification:  Blood
samples were collected from each subject (5 ml) and genomic
DNA was isolated using the Qiagen QiaAmp Blood mini kit
(Qiagen, Valencia, CA). IL-1β C(-511)T and C(+3953)T
genotyping of genomic DNA were determined with poly-
merase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) technique. A 304 bp PCR fragment of the
IL-1β (-511) in the promoter region was amplified using the
following primers: F5'-TGG CAT TGA TCT GGT TCA TC-3'
and R5'-GTT TAG GAA TCT TCC CAC TT-3'. PCR condi-
tions were as follows: a denaturing step of 95 °C for 10 min,
then 35 cycles of 95 °C for 45 s, 60 °C for 45 s, 72 °C for 1
min, and a final incubation at 72 °C for 5 min. The products
were digested with Bsu36I (New England Biolabs, Inc.,
Beverly, MA) at 37 °C for 3 h and were run on ethidium bro-
mide-stained 2% agarose gel. This gave products that either
remained intact (C allele) or were cut into two fragments of
190 and 114 bp (T allele).
The polymorphic region containing the TaqI (New En-
gland Biolabs, Inc.) restriction site at position +3953 within
exon 5 of the IL-1β gene was amplified using the following
primers: F5'-GTT GTC ATC AGA CTT TGA CC-3' and 5'-
TTC AGT TCA TAT GGA CCA GA-3'. The PCR conditions
were the same as described in the previous. The products were
digested with TaqI at 65 °C for 3 h. TaqI digestions of the 249
bp fragments were cut into two fragment of 135 and 114 bp
(allele C) or remained intact (allele T).
Statistical analysis:  Genotype and allele frequencies be-
tween the control and NTG groups were compared using the
chi-square test and Fisher’s exact test, respectively. Age and
gender were compared between the control and NTG groups
using the Student’s t-test and Fisher’s exact test, respectively.
Odds ratios were computed to assess the strength of associa-
tion between the presence of each genotype and the clinical
diagnosis of NTG. A p value of less than 0.05 was defined to
be of statistical significance. All statistical analyses were per-
formed using SPSS 10.0 (SPSS Inc., Chicago, IL).The power
calculation was carried out according to the method by
Schlesselman [17].
RESULTS
 The study consisted of 231 NTG patients (127 men, 104
women) and 245 normal controls (135 men, 110 women). The
mean age was 70 years for the NTG patients (range 31-85)
and 71 years for the controls (range 30-85). There was no dif-
ference between the control and NTG groups in age (p>0.05,
t-test) and gender (p>0.05, Fisher’s exact test). The mean and
standard deviation of the maximum IOP was 17.5±2.1 mmHg
for the NTG patients and 16.9 ±2.3 mmHg for the control sub-
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TABLE 1. GENOTYPE AND ALLELE FREQUENCIES OF INTERLEUKIN-1β
(-511) AND INTERLEUKIN-1β (+3953)
     Genotype        NTG (%) n= 231   Control (%) n=245    χ2    p-value
------------------   --------------   -----------------   ----   -------
IL-1β (-511)
Genotype
C/C                    70 (30.3%)         61 (24.9%)
C/T                   108 (46.8%)        125 (51.0%)      1.77     0.4
T/T                    53 (22.9%)         59 (24.1%)
Allele
C                     248 (53.7%)        247 (50.4%)      1.02     0.3
T                     214 (46.3%)        243 (49.6%)
IL-1β (+3953)
Genotype
C/C                   214 (93.8%)        226 (92.2%)
C/T                    16 ( 6.9%)         18 ( 7.3%)      0.03     0.98
T/T                     1 ( 0.4%)          1 ( 0.4%)
Allele
C                     444 (96.1%)        470 (95.9%)      0.02     0.88
T                      18 ( 3.9%)         20 ( 4.1%)
There was no statistically significant difference in genotype frequency
(GF) or allele frequency (AF) distribution of the two polymorphisms
between NTG and control subjects. The breakdown was as follows:
For IL-1β -511, the AF was p=0.3 and the GF was p=0.4; for IL-1?
+3953, the AF was p=0.88 and the GF was p=0.98.
720jects. No deviations from Hardy-Weinberg equilibrium could
be seen in NTG patients and control studies.
The genotype and allele frequencies of the IL-1β (-511)
and IL-1β (+3953) polymorphism in NTG and control sub-
jects are presented in Table 1. There was no statistically sig-
nificant difference in genotype frequency (GF) or allele fre-
quency (AF) distribution of the two polymorphisms between
NTG and control subjects. (IL-1β -511 AF: p=0.3, GF: p=0.4;
IL-1β +3953 AF: p=0.88, GF: p=0.98)
The statistical power over 80% suggested that the prob-
ability of detecting a difference could be believable in this
sample size.
DISCUSSION
 Mutations in three genes (myocilin, optineurin, and WDR36)
have been implicated in NTG [18-22]. Mutation in the
optineurin gene was initially reported in 16.7% of families
with hereditary primary open angle glaucoma (POAG), with
most of them having NTG [19]. Aung et al. [23] and Powell et
al. [24] reported that NTG demonstrates an association with
polymorphisms of the OPA1 gene on chromosome 3, which is
responsible for dominant optic atrophy in the Caucasian popu-
lation [25]. Many more important gene variants have recently
been associated with glaucoma risk, such as apolipoprotein E
(APOE) [26,27], endothelin receptor type A gene (EDNRA)
[28,29], IL-1α [30], methylenetetrahydrofolate reductase
(MTHFR) [31,32], and beta-adrenergic receptors [33]. How-
ever, these genes cannot interpret the overall inheritance sus-
ceptibility of NTG pathogenesis. The other associations in-
volved in the development of NTG should be further investi-
gated.
Recent evidence indicates a close link between chronic
neurodegenerative disease and IL-1β expression. Polymor-
phism in the IL-1 gene clusters have been shown in myasthe-
nia gravis, multiple sclerosis, Parkinson’s disease, temporal
lobe epilepsy with hippocampal sclerosis and Alzheimer’s dis-
ease [34-38]. NTG may be a chronic neurodegeneration like
Alzheimer’s disease, considering the potential similarities in
cellular events leading to neurodegeneration between
Alzheimer’s disease and glaucoma. There is evidence that IL-
1β upregulates the production and processing of β-amyloid
protein in neurons [39] as well as the expression and activity
of acetylcholine esterase [40]. Furthermore, it has been shown
that IL-1β activated microglia selectively killed cholinergic
neurons in Alzheimer’s patients [41]. The death of retinal gan-
glion cells in glaucoma involving chronic β-amyloid neuro-
toxicity mimics Alzheimer’s disease at the molecular level [7].
Our study was designed to see whether patients with NTG
had a higher risk of developing the disease as a result of their
IL-1β genotype.
NTG has been considered a subtype of POAG, sharing
many similar characteristics. However, some studies show a
connection between abnormal autoimmunity and NTG, sug-
gesting the disease is affected more by antibodies damaging
retinal ganglion cells and inducing apoptosis [42]. Lin et al.
[43] found that IL-1β (+3953) T allele was significantly more
common in POAG patients than in control subjects in a Chi-
nese population. However, there was no association between
the IL-1β (position -511 and +3953) polymorphisms and NTG
in our study. The dissimilar findings revealed that the patho-
genesis and effect of IL-1β may be different between NTG
and POAG. IL-1β may not have a significant role in the patho-
genesis of the optic neuropathy.
Genes coding for the two isoforms of IL-1 (IL-1α and
IL-1β) and for the IL-1 receptor antagonist (IL-1RA) are lo-
cated within the IL1 gene cluster at chromosomal locus 2q13
[44]. Polymorphisms within this gene cluster have been asso-
ciated with a large variety of human diseases [45]. Some of
these polymorphisms have been shown to alter the amount of
IL-1 produced [46-49]. These allelic variants are known to
alter function. The C/T polymorphism at position -511 in the
promoter region of IL-1β regulates the production of IL-1β
protein and in vitro synthetic capacity of C/C genotype carri-
ers are lower than that of C/T of T/T carriers [50]. The ho-
mozygosity for the IL-1β (+3953T) allele has been associated
with a fourfold increase in the production of IL-1β when com-
pared to homozygosity for IL-1β (+3953C) allele [47].
Lack of association between IL-1β genetic polymorphism
and NTG was observed in our study of a Chinese population.
In our control group, the allele frequencies of the IL-1β (-511)
were similar to those previous reported in other controls
[43,51,52]. The frequency of IL-1β (-511) C allele and IL-1β
(+3953) T allele were significantly lower among Chinese popu-
lations compared to Caucasians [53]. The observed negative
association could be due to the low frequency of the IL-1β (-
511) C allele and IL-1β (+3953) T allele in a Chinese popula-
tion. Further studies with NTG cohort of different ethnic back-
ground are required to further define this association. We can-
not exclude the possibility of IL-1β (-511) and IL-1β (+3953)
polymorphism being associated with NTG in different ethnic
population or the likelihood of an association between NTG
and another IL-1β polymorphism. The lack of an association
of the common polymorphisms of the IL-1β with NTG in
Chinese population suggests this factor may not have a sig-
nificant role in the pathogenesis of the optic neuropathy.
In conclusion, we found no significant associations be-
tween polymorphisms in the IL-1β (-511 and +3953) and NTG
in a Chinese population. However, the possibility of other mu-
tations or sequence change in the IL-1β gene cannot be ex-
cluded. Further genetic studies of NTG are necessary to in-
vestigate the development of the neurodegenerative process.
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